Stefan Linn

Stefan Linn has a diverse work experience spanning multiple industries. Stefan has held board member positions at Sun Wave Pharma since 2022 and served as chairman of Remedica, Destination Pet, LLC, and K2 HealthVentures from 2020 to present. Stefan was also managing partner and CEO of L1 Health at LetterOne since 2020. Prior to that, they were an investor and operating executive at Holexion from 2016. Stefan served as the chief operating officer at Oxford Immunotec from 2017 to 2020 and held senior vice president roles at IMS Health from 2010 to 2016 and at McKesson from 2001 to 2007. Stefan started their career as a director at TPG Capital in 2007.

Stefan Linn attended The University of Dallas from 1985 to 1987, where they earned a Bachelor of Arts degree in Economics. Stefan later pursued a Master of Business Administration (MBA) from the University of California, Berkeley, from 1987 to 1989.